Imatinib 400mg tablets
NHS hospitals in England used £79,598,336 of indicative cost of Imatinib 400mg tablets in the 12 months to July 2026, about 0.3% of all hospital medicines spend. That is up 5.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Imatinib 400mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Imatinib 400mg tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £2,644,700 |
| The Christie Nhs Foundation Trust | £2,630,052 |
| University Hpls Of Leicester Nhs Trust | £2,286,931 |
| University College London Foundation Tr | £2,139,597 |
| The Royal Marsden Nhs Foundation Trust | £2,105,385 |
| Barts Health Nhs Trust | £2,016,697 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,918,079 |
| Leeds Teaching Hpls Nhs Trust | £1,914,429 |
| Oxford University Hospitals Nhs Ft | £1,708,640 |
| Univ Hpls Bristol Nhs Foundation Trust | £1,461,627 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.